Efficacy and safety of twice-daily accelerated hyperfractionated re-irradiation for thoracic malignancies.

ABSTRACT:

Introduction

Balancing the demands for dose-escalated re-irradiation with toxicity to organs at risk (OARs) is a challenge. Twice-daily (BID) accelerated hyperfractionated re-irradiation (re-RT) is a potential solution, yet there is no guidance for its application for thoracic malignancies.

Methods

All BID thoracic re-RT cases at our institution since 2014 were reviewed. Prior radiation courses were deformably registered. Summary plan dosimetrics were extracted using per-voxel cumulative EQD2 (α/β = 3 for normal tissues). Maximum toxicity following BID re-RT was graded per CTCAE v5.0 and assessed for relationship to radiation. Local failure (LF), progression-free survival (PFS), and overall survival (OS) were measured and compared between subgroups based on histology, re-RT

SUBMITTER: Doss VL 

PROVIDER: S-EPMC12703687 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature